Literature DB >> 12911628

Lipopolysaccharide-induced dopaminergic cell death in rat midbrain slice cultures: role of inducible nitric oxide synthase and protection by indomethacin.

Haruki Shibata1, Hiroshi Katsuki, Mayumi Nishiwaki, Toshiaki Kume, Shuji Kaneko, Akinori Akaike.   

Abstract

Glial cell activation associated with inflammatory reaction may contribute to pathogenic processes of neurodegenerative disorders, through production of several cytotoxic molecules. We investigated the consequences of glial activation by interferon-gamma (IFN-gamma)/lipopolysaccharide (LPS) in rat midbrain slice cultures. Application of IFN-gamma followed by LPS caused dopaminergic cell death and accompanying increases in nitrite production and lactate dehydrogenase release. Aminoguanidine, an inhibitor of inducible nitric oxide synthase (iNOS), or SB203580, an inhibitor of p38 mitogen-activated protein kinase, prevented dopaminergic cell loss as well as nitrite production. SB203580 also suppressed expression of iNOS and cyclooxygenase-2 (COX-2) induced by IFN-gamma/LPS. A COX inhibitor indomethacin protected dopaminergic neurons from IFN-gamma/LPS-induced injury, whereas selective COX-2 inhibitors such as NS-398 and nimesulide did not. Notably, indomethacin was able to attenuate neurotoxicity of a nitric oxide (NO) donor. Neutralizing antibodies against tumour necrosis factor-alpha and interleukin-1beta did not inhibit dopaminergic cell death caused by IFN-gamma/LPS, although combined application of these antibodies blocked lactate dehydrogenase release and decrease in the number of non-dopaminergic neurons. These results indicate that iNOS-derived NO plays a crucial role in IFN-gamma/LPS-induced dopaminergic cell death, and that indomethacin exerts protective effect by mechanisms probably related to NO neurotoxicity rather than through COX inhibition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12911628     DOI: 10.1046/j.1471-4159.2003.01929.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  14 in total

1.  The effects of age and lipopolysaccharide (LPS)-mediated peripheral inflammation on numbers of central catecholaminergic neurons.

Authors:  P R Mouton; B Kelley-Bell; D Tweedie; E L Spangler; E Perez; O D Carlson; R G Short; R deCabo; J Chang; D K Ingram; Y Li; N H Greig
Journal:  Neurobiol Aging       Date:  2010-11-19       Impact factor: 4.673

2.  Glial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons against lipopolysaccharide neurotoxicity.

Authors:  Bin Xing; Tao Xin; Lingling Zhao; Randy L Hunter; Yan Chen; Guoying Bing
Journal:  J Neuroimmunol       Date:  2010-05-14       Impact factor: 3.478

3.  Lipopolysaccharide induces cell death in cultured porcine myenteric neurons.

Authors:  Marcin Arciszewski; Stefan Pierzynowski; Eva Ekblad
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

4.  Caffeic acid phenethyl ester protects nigral dopaminergic neurons via dual mechanisms involving haem oxygenase-1 and brain-derived neurotrophic factor.

Authors:  Y Kurauchi; A Hisatsune; Y Isohama; S Mishima; H Katsuki
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

5.  Ibuprofen fails to prevent brain pathology in a model of neuropsychiatric lupus.

Authors:  David A Ballok; Xiaoxing Ma; Judah A Denburg; Larry Arsenault; Boris Sakic
Journal:  J Rheumatol       Date:  2006-11       Impact factor: 4.666

6.  Lipopolysaccharide preconditioning induces protection against lipopolysaccharide-induced neurotoxicity in organotypic midbrain slice culture.

Authors:  Ye Ding; Liang Li
Journal:  Neurosci Bull       Date:  2008-08       Impact factor: 5.203

Review 7.  Reducing substance use during adolescence: a translational framework for prevention.

Authors:  Jessica J Stanis; Susan L Andersen
Journal:  Psychopharmacology (Berl)       Date:  2014-01-25       Impact factor: 4.530

Review 8.  The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery.

Authors:  Garima Dutta; Ping Zhang; Bin Liu
Journal:  Fundam Clin Pharmacol       Date:  2008-08-15       Impact factor: 2.748

9.  A possible novel anti-inflammatory mechanism for the pharmacological prolyl hydroxylase inhibitor 3,4-dihydroxybenzoate: implications for use as a therapeutic for Parkinson's disease.

Authors:  Shankar J Chinta; Subramanian Rajagopalan; Abirami Ganesan; Julie K Andersen
Journal:  Parkinsons Dis       Date:  2012-05-14

10.  Aromatic-Turmerone Analogs Protect Dopaminergic Neurons in Midbrain Slice Cultures through Their Neuroprotective Activities.

Authors:  Yuria Hori; Reiho Tsutsumi; Kento Nasu; Alex Boateng; Yasuhiko Ashikari; Masaharu Sugiura; Makoto Nakajima; Yuki Kurauchi; Akinori Hisatsune; Hiroshi Katsuki; Takahiro Seki
Journal:  Cells       Date:  2021-05-03       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.